retatrutide phase 2 obesity nejm 2023 jastreboff 🚨 BREAKING: Shows “Bariatric-Level” Weight Loss in 3 Trial New Phase 3 TRIUMPH-1 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most Ania Jastreboff, MD, PhD |
Description
The OASIS 1 clinical trial (sponsored by Novo Nordisk) studied oral semaglutide for weight management over 68 weeks
During rapid weight loss, protein is the single most important macronutrient for preserving lean tissue
That trial documented -81.4% hepatic fat fraction reduction with 85% of patients reaching resolution ( 9 weight points over a shorter window
Mona zacz np
People who used Wegovy, or similar GLP-1 medications and later developed serious gastrointestinal injuries may have a potential claim, depending on diagnosis, timing, medical history, warning information, and other facts
